EGFR and non-small cell lung carcinoma: Furthermore, in advanced NSCLC patients treated with EGFR-TKIs, high CEA and/or low Cyfra21-1 levels significantly correlated with higher responses and longer survival, especially in patients with unknown EGFR mutation status or with squamous cell carcinoma diagnosis [20].